EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization
- PMID: 12620237
- DOI: 10.1016/s1097-2765(03)00047-9
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization
Abstract
Epidermal growth factor (EGF) receptor is the prototype of the ErbB (HER) family receptor tyrosine kinases (RTKs), which regulate cell growth and differentiation and are implicated in many human cancers. EGF activates its receptor by inducing dimerization of the 621 amino acid EGF receptor extracellular region. We describe the 2.8 A resolution crystal structure of this entire extracellular region (sEGFR) in an unactivated state. The structure reveals an autoinhibited configuration, where the dimerization interface recently identified in activated sEGFR structures is completely occluded by intramolecular interactions. To activate the receptor, EGF binding must promote a large domain rearrangement that exposes this dimerization interface. This contrasts starkly with other RTK activation mechanisms and suggests new approaches for designing ErbB receptor antagonists.
Similar articles
-
Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor.J Biochem. 1997 Jul;122(1):116-21. doi: 10.1093/oxfordjournals.jbchem.a021718. J Biochem. 1997. PMID: 9276679
-
Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation.Biochemistry. 1993 Aug 17;32(32):8193-8. doi: 10.1021/bi00083a020. Biochemistry. 1993. PMID: 8347619
-
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.Cell. 2002 Sep 20;110(6):775-87. doi: 10.1016/s0092-8674(02)00963-7. Cell. 2002. PMID: 12297050
-
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.Cell. 2002 Sep 20;110(6):669-72. doi: 10.1016/s0092-8674(02)00966-2. Cell. 2002. PMID: 12297041 Review.
-
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.Mol Cell. 2003 Sep;12(3):541-52. doi: 10.1016/s1097-2765(03)00350-2. Mol Cell. 2003. PMID: 14527402 Review.
Cited by
-
Microplate-compatible total internal reflection fluorescence microscopy for receptor pharmacology.Appl Phys Lett. 2013 May 13;102(19):193702. doi: 10.1063/1.4805041. Epub 2013 May 14. Appl Phys Lett. 2013. PMID: 23825800 Free PMC article.
-
Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches.J Pers Med. 2022 Oct 4;12(10):1651. doi: 10.3390/jpm12101651. J Pers Med. 2022. PMID: 36294789 Free PMC article. Review.
-
Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.J Immunol. 2013 Jul 1;191(1):217-27. doi: 10.4049/jimmunol.1300231. Epub 2013 May 22. J Immunol. 2013. PMID: 23698748 Free PMC article.
-
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.Biomol Ther (Seoul). 2022 Jan 1;30(1):19-27. doi: 10.4062/biomolther.2021.047. Biomol Ther (Seoul). 2022. PMID: 34074804 Free PMC article. Review.
-
Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors.J Mol Med (Berl). 2005 Dec;83(12):976-83. doi: 10.1007/s00109-005-0699-4. Epub 2005 Aug 31. J Mol Med (Berl). 2005. PMID: 16133419
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous